Trial Profile
A Phase 3, Prospective, Randomized, Double-Blind, Placebo Controlled, Multi-center Study of SC411 for Sickle Cell Disease
Status:
Not yet recruiting
Phase of Trial:
Phase III
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Docosahexaenoic acid (Primary)
- Indications Sickle cell anaemia
- Focus Therapeutic Use
- Acronyms SCOT
- Sponsors Micelle BioPharma
- 30 Jan 2019 Planned number of patients changed from 213 to 210.
- 30 Jan 2019 Status changed from recruiting to not yet recruiting.
- 30 Jan 2019 Planned End Date changed from 1 Jan 2020 to 1 Dec 2020.